The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
SOHO 2024 live congress feed
Stay up to date with the latest developments in ALL from the SOHO 2024 Annual Meeting with our live social media coverage.
CONGRESS | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 6, 2024
Elias Jabbour, @MDAndersonNews shares data of D-D Mini-HCVD-inotuzumab-blinatumomab for the treatment of R/R ALL; concluding with the feasibility of the combination based on safety and efficacy data. Overall 1-year OS 90% vs 66%.#ALLsm #leusm pic.twitter.com/F93s1biTkK
CONGRESS | POSTER | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 5, 2024
Ajibade Ashaye presents a comparison of the effects of ponatinib vs imatinib in newly diagnosed Ph+ ALL on patient-reported outcomes from the phase III PhALLCON trial (PRO evaluable population N=238).
Ponatinib was associated with significant and… pic.twitter.com/0Xpz7aFBrf
CONGRESS | POSTER | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 5, 2024
Elias Jabbour, MD @MDAndersonNews presents an in-depth responder analysis of the phase III PhALLCON trial investigating ponatinib vs imatinib in newly diagnosed Ph+ ALL (N=245).
Pts receiving ponatinib experienced clinically meaningful and… pic.twitter.com/iPiGFN8mF5
CONGRESS | POSTER | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 5, 2024
Ajibade Ashaye presents an analysis of MRD-negative complete remission as a prognostic indicator of long-term survival outcomes (OS and EFS) in pts with Ph+ ALL from a systemic literature review.
Deeper responses at end of induction/end of… pic.twitter.com/eHfgYdEf1o
CONGRESS | #SOHO2024
— ALL Hub (@ALL_Hub_) September 4, 2024
Rayne Rouce @bcmhouston presents on the evolution of tisagenlecleucel for the treatment of pediatric and young adult R/R B-ALL.
Safety outcomes were favorable and did not change greatly, patients are receiving tisagenleucel earlier in their treatment course,… pic.twitter.com/MM9LzOiZHP
CONGRESS | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 4, 2024
Josep Maria Ribera @CarrerasIJC debates that Ph + ALL is best treated with chemotherapy and transplant; concluding that in most cases allo-HSCT is important with 1st or 2nd gen TKI and in 3rd gen TKI where there is a lack of CMR or IKZF1+ signature.#ALLsm… pic.twitter.com/kZQMinWIkU
CONGRESS | #SOHO2024
— ALL Hub (@ALL_Hub_) September 4, 2024
Elias Jabbour, @MDAndersonNews debates that Ph + ALL can be treated with chemotherapy free regimens and without transplant. Key points include: omit allo-SCT in certain patients who could be cured without , CAR T could be considered, and new drugs to be… pic.twitter.com/ZEN3v57WhJ
CONGRESS | #SOHO2024 |
— ALL Hub (@ALL_Hub_) September 4, 2024
Partow Kebriaei @MDAndersonNews provides an overview on transplant in #ALL. Key points include: MRD is the leading factor to determine transplant, transplant may be considered in first remission, and transplant consolidation after CAR T may be effective in… pic.twitter.com/i8zxDfiB7q
Only 1 day to go!
— ALL Hub (@ALL_Hub_) September 3, 2024
The ALL Hub will be covering #SOHO2024.
Sep 4–7
Houston, US, and online
We’ll be providing live social media coverage.
Keep an eye on our socials to see the latest updates!
#allsm #leusm @SocietyofHemOnc pic.twitter.com/rnQ22bXnTX
CONGRESS | #SOHO2024 @MRLitzow @MayoClinic discusses incorporating immunotherapies, blinatumomab and InO, into upfront #ALL therapy; concluding that both these agents can improve outcomes in MRD- ALL and may be combined with or sequenced with chemotherapy.#ALLsm #leusm pic.twitter.com/7oUO0GLP2t
— ALL Hub (@ALL_Hub_) September 4, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
